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ABSTRACT: 
Neuregulin1 (Nrg1) and its receptors ErbB are crucial for heart development and for adult 
heart structural maintenance and function and Nrg1 has been proposed for heart failure 
treatment. Infarct size is the major determinant of heart failure and the mechanism of action 
and the role of each ErbB receptor remain obscure, especially in the post-ischemic 
myocardium. We hypothesized that Nrg1 and ErbB are affected at transcriptional level early 
after ischemia/reperfusion (I/R) injury, and that the protective postconditioning procedure 
(PostC, brief cycles of ischemia/reperfusion carried out after a sustained ischemia) can 
influence this pathway. The Langendorff’s heart was used as an ex-vivo model to mimic an I/R 
injury in the whole rat heart; after 30 min of ischemia and two hours of reperfusion, with or 
without PostC, Nrg1 and ErbB expression were analyzed by quantitative real-time PCR and 
Western blot. While no changes occur for ErbB2, ErbB4 and Nrg1, an increase of ErbB3 
expression occurs after I/R injury, with and without PostC. However, I/R reduces ErbB3 
protein, whereas PostC preserves it. An in vitro analysis with H9c2 cells exposed to redox-
stress indicated that the transient over-expression of ErbB3 alone is able to increase cell 
survival (MTT assay), limiting mitochondrial dysfunction (JC-1 probe) and apoptotic signals 
(Bax/Bcl-2 ratio). This study suggests ErbB3 as a protective factor against death pathways 
activated by redox stress and supports an involvement of this receptor in the pro-survival 
responses. 
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1. Introduction 
Neuregulin1 (Nrg1) is a signalling protein belonging to the Epidermal Growth Factor (EGF) 
gene family that mediates various cellular processes, such as cell growth, survival, migration, 
in different cell types, through the ErbB receptors. Nrg1/ErbB system is essential for a correct 
cardiac development, as demonstrated by the lethal effects of its depletion at embryonic 
stages [1,2]. Furthermore, it is now clear that also in adult heart this signalling plays a critical 
role in the normal function as well as in ischemia or other pathological conditions [3,4]. In the 
NRG1 gene, alternative splicing gives rise to different isoforms and, in adult heart, cardiac 
microvascular endothelial cells (EC) express soluble Nrg1 isoforms (type I and type II), both 
alpha and beta variants [5], which stimulate cell survival and growth [6], glucose up-take [5], 
protein synthesis and “hypertrophic” gene expression [7]. Nrg1 mediated the cross-talk 
between EC and cardiomyocytes that express ErbB receptors [8], and the deletion of Nrg1 
from EC increases the infarct area and the number of TUNEL positive cells after ischemia and 
reperfusion (I/R) injury [9]. 
ErbB receptors belong to the tyrosine kinase receptor family, and work as dimers. Among the 
four ErbB receptors only ErbB3 and ErbB4 can bind directly Nrg1; ErbB3 signals only as 
heterodimer and ErbB2 is the preferred partner for heterodimerization, while ErbB4 can 
form both homo and heterodimers. Initially only ErbB1, ErbB2 and ErbB4 were thought to be 
expressed in adult heart. In 2011, Camprecios and colleagues demonstrated that mouse post-
natal cardiomyocytes express a functional ErbB3 protein that is localized mainly in the outer 
areas of T-Tubules with a non-uniform distribution [10]. Although a methylation of ERBB3 
gene has been observed in human dilated cardiomyopathy [11], the function of ErbB3 in adult 
heart remains still unknown. Recently, it has been demonstrated that a E3 ligase known as 
“neuregulin receptor degradation protein-1” (Nrdp1), which targets specifically ErbB3 [12], is 
upregulated after I/R injury. The mouse model over-expressing Nrdp1 is characterized by 
higher infarct size, increased TUNEL-positive nuclei and inflammatory cells [13]. It was 
postulated that Nrdp1 is a pro-apoptotic signal in heart during I/R injury and that its action is 
mediated principally by the degradation of ErbB3.  
For its pro-survival effect Nrg1 has been proposed as a potential drug for heart failure 
treatment. Several pre-clinical studies in rat or mouse models of heart failure and two clinical 
trial [14,15] demonstrated that intravenous administration of recombinant soluble Nrg1 
improved cardiac contractility and relaxation [16,17], left ventricular remodelling [18], 
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decreased apoptosis [19] and attenuated mitochondrial dysfunction [18]. However, the 
molecular bases of this beneficial effect remain unclear. 
It has not yet been investigated whether Nrg1/ErbB system is modulated by existing 
therapeutic strategies aimed to protect the heart against ischemia and reperfusion injury. One 
of the most interesting cardioprotective strategy is the so-called “Postconditioning” (PostC, 
i.e., brief cycles of ischemia/reperfusion carried out after a sustained ischemia) [20–23], 
which can reduce the infarct size in animal models [24,25] and humans [26–28]. The 
cardioprotective mechanisms activated by PostC comprise the activation of multiple 
pathways, including the so-called RISK (Akt/ERK/GSK3-β) and SAFE (JNK/STAT3) pathways 
[29–31]. Since these pathways are downstream of the Nrg1/ErbB system [29, 30, 31], which 
in PostC context is scarcely investigated, we studied how this system is influenced by I/R and 
the PostC procedures.  
We analysed the early changes in Nrg1/ErbB system following ischemia/reperfusion injury in 
isolated rat heart, with or without the PostC treatment. Moreover, we investigated in a 
cardiomyocyte cell line whether the ErbB3 receptor plays a role in oxidative stress.  
Overall results suggest that this receptor can be involved in the myocardial response to 
ischemia and reperfusion challenge. In particular, we confirmed that ErbB3 is expressed in rat 
adult heart and we demonstrated, for the first time, that its expression is upregulated in post-
ischemic heart, suggesting that ErbB3 protein might play a role in PostC and oxidative injury 
limitation. 
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional 
Repository 
2. Methods 
2.1 Animals 
Male Wistar rats (n=18, 5–6 month old, body weight 450–550 g) were purchased from Harlan 
(Bresso, MI, Italy). Animals received care in compliance with the Italian law (DL-116, January 
27, 1992) and with the European Directive 2010/63/EU on the protection of animals used for 
scientific purposes. These laws are in accordance with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 
85–23, revised 1996).  
 
2.2 Langendorff’s heart model 
Methods for Langendorff’s isolated rat hearts were similar to those previously described 
[32,33]. In brief, each animal was weighed and treated with heparin (800 U/100 g b.w., i.m.). 
Then, 10 min afterwards, animal was sacrificed, the heart was rapidly excised and placed in 
ice-cold buffer solution and weighed. Isolated hearts were retrogradely perfused at constant 
flow (9 ± 1 ml/min/g) with oxygenated Krebs–Henseleit buffer (127 mM NaCl, 17.7 mM 
NaHCO3, 5.1 mM KCl, 1.5 mM CaCl2, 1.26 mM MgCl2, 11 mM D-glucose) (Sigma-Aldrich, St. 
Louis, MO, USA) gassed with 95% O2 and 5% CO2, paced at 280 bpm and kept in a 
temperature-controlled chamber (37°C).  
 
2.3 Experimental Protocols 
After 20 min of stabilization, hearts were randomly divided in three groups: (1) Control group 
(Sham), hearts were subjected to 150 min perfusion only; (2) I/R group, hearts underwent 30 
min of global ischemia and then a period of 120 min full reperfusion; (3) PostC group, after 30 
min ischemia, hearts underwent a PostC protocol (5 cycles of 10 sec reperfusion and 10 sec of 
global ischemia) then a period of 120 min full reperfusion [24].  
 
2.4 Myocardial Injury  
2.4.1. Infarct size 
Immediately after reperfusion each heart was quickly removed from the perfusion apparatus 
and the apical part of the heart was collected and frozen for biomolecular analysis. The 
remaining basal part of the left ventricle was dissected into 2-3 mm circumferential slices. 
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Following 20 min of incubation at 37°C in 0.1% solution of nitro-blue tetrazolium in 
phosphate buffer, unstained tissue was carefully separated from stained tissue by an 
independent observer. The unstained tissue represents the amount of death cells, the stained 
tissue represents the viable cells. A gravimetric method was used: the unstained mass was 
weighed and then expressed as a percentage of left ventricular mass [24,32,33]. Reagents 
necessary to assess myocardial infarction were purchased from Sigma (USA).  
 
2.4.2. Lactate dehydrogenase analysis 
Since in isolated rat hearts PostC is known to reduce the production of lactate dehydrogenase 
(LDH) during reperfusion, the release of this enzyme was tested. Samples of coronary effluent 
(2 ml) were collected with a catheter inserted into the right ventricle via the pulmonary 
artery. Samples were collected immediately before ischemia during reperfusion. Thereafter 
samples were collected every 20 min until the end of reperfusion. LDH release was measured 
as previously described and data are expressed as cumulative values for the entire 
reperfusion period [24,32].  
 
2.5. RNA isolation and cDNA preparation 
Total RNA was extracted from half apex from each heart, previously dissociated by pestles, 
with TRIzol (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's 
instructions. Glycogen (5 μg) was added as a carrier to facilitate RNA precipitation. For each 
sample 1μg total RNA was reverse transcripted (RT): samples were warmed at 65 °C for 5 
minutes and the reaction was carried out in 20 μl containing: 1 × RT-Buffer (Life 
Technologies), 0.1 μg/μl bovine serum albumin (BSA, Promega, Fitchburg, WI, USA), 0.5 mM 
dNTPs, 7.5μM random decamers (Life Technologies), 5mM DTT (Life Technologies), 40 U 
RNAse Out Inhibitor and 200U SUPERSCRIPT III Rev transcript (Life Technologies,18080044). 
The reaction was performed for 10 min at 25 °C, 90 min at 50 °C, 15 min at 70 °C. The 
obtained cDNA was diluted 10 folds with water and stored at -20 °C. 
 
2.6. Quantitative real-time PCR (qRT-PCR) analysis 
Quantitative real-time PCR analysis was performed in a 7300 real-time PCR system (Applied 
Biosystems). The reaction was carried out in 20 µl containing 5 µl diluted cDNA 
(corresponding to 25 ng of starting RNA), 1x Sybr Green PCR Master Mix (Bio-Rad, Hercules, 
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CA, USA) and 300nM forward and reverse primers. For each sample a technical triplicate was 
performed. All primers were designed to amplify specific isoforms of ErbB receptors or 
Neuregulin-1 and Nrdp1 (Table 1). The reaction was carried out with the following protocol: 
30 seconds (sec) at 95°C, 40 cycles of denaturation at 95 °C for 15 sec followed by primer 
annealing and elongation at 60 °C for 1 minute. Dissociation curve was always analysed to 
control the quality of the reaction. 
Data were analyzed by the ΔΔCt relative quantification method normalizing to the geometric 
average of two housekeeping genes, Ubiquitin C (UbC) and Hypoxanthine guanine 
phosphoribosyltransferase (HPRT). We determined the difference between Ct values of target 
and housekeeping gene (ΔCt), the difference between the ΔCt values of the samples and the 
ΔCt mean value of control sample was then calculated (ΔΔCt). The normalized relative 
quantity (NRQ) was determined using the formula: NRQ=2-(ΔΔCt). NRQ value >1 reflects an 
increasing of target gene expression, NRQ<1 reflects a decreasing of target gene expression 
[34]. The analysis was carried out in biological quintuplicate (for each experimental group 
n=5) and results were expressed as mean ± standard deviation. 
 
2.7. Total protein extraction and Western Blot analysis 
Total proteins were extracted from heart apexes with boiling Laemmli buffer (2.5% SDS, 
0.125M Tris–HCl pH 6.8) dissociating the tissue with pestles and incubating the protein 
extract at 100°C for 3 minutes. The BCA method was used to quantify proteins and the same 
amount of protein for each sample was loaded for SDS-PAGE analysis. Proteins were 
transferred to a nitrocellulose membrane (Bio-Rad, 162-0093). Primary antibodies used are: 
rabbit polyclonal anti-ErbB3 (working dilution, w.d., 1:1000, sc-285, Santa Cruz, Santa Cruz, 
CA, USA), anti-ErbB2 (w.d. 1: 1000, sc-284, Santa Cruz), anti-alpha sarcomeric actinin (w.d. 
1:2500, A7811, SIGMA), anti-phospho S6 ribosomal protein (w.d. 1:2000, 4858, Cell 
Signaling). The secondary antibodies used are: ECLTM anti-rabbit IgG (w.d. 1:40000, NA934, 
GE Healthcare, Little Chalfont, Buckinghamshire, UK) and ECLTM anti-mouse IgG (w.d. 
1:40000, NA931, GE Healthcare). The western blot quantitative analysis was performed using 
the Image J program. 
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2.8. Cell culture and in vitro experiments 
For the in vitro analysis we used H9C2 cells, a rat myoblast cell line provided by American 
Collection of Cell Cultures (ATCC® CRL-1446™ Milan Italy). Cells were cultured in Dulbecco’s 
Modified Eagle’s Medium Nutrient mixture F-12 HAM (DMEM, D8437, SIGMA) supplemented 
with 10% fetal bovine serum (FBS, GIBCO, Life Technologies) and 1% (v/v) 
streptomycin/penicillin (Wisent Inc, Quebec, Canada).  
To express the ErbB3 protein, the expression vector pcDNA3-B3, kindly provided by Dr. John 
G. Koland (Department of Pharmacology, University of Iowa, College of Medicine, Iowa City, 
IA) was used [35]. For transient transfections, Lipofectamine 2000 (Life Technologies) was 
used following manufacturer’s instruction. Briefly, cells were grown in 20cm2 dishes, then 
medium was changed to Optimem (Life Technologies) and cells were transfected with 4µg 
plasmid DNA and 4µl Lipofectamine 2000. Control mock transfections were carried out with 
the empty vector pcDNA3. After 16 hours the medium was changed to normal culture medium 
and after other 24 hours cells were detached and left to grow in 60 mm dish.  
For the oxidative stress we treated H9C2, H9C2-ErbB3 and H9C2-mock cells with hydrogen 
peroxide solution (H202, H1009, SIGMA), used for 2 hours, in a range of concentration 100 
µM-300 µM to obtain 40-50% of cell mortality. Untreated H9c2 were compared to H9c2 
exposed to 50 ng/ml Nrg1-β1 (recombinant human NRG1-β1/HRG1-β1 extracellular domain, 
# 377-HB-050, R&D Systems, Minneapolis, MN).  
A pre-treatment of the cells with 50 ng/ml Nrg1 for 2 h was also performed, followed by the 
oxidative stress with hydrogen peroxide solution. Cell survival rate was obtained using the 
thiazolyl blue tetrazolium bromide (MTT, M2128, SIGMA) assay, following producer’s 
instruction. Cell survival rate of each cell group were analysed separately. For each 
independent experiment, data for each condition were calibrated to the control (“no stress”) 
sample. 
For Bax and Bcl-2 analysis, cells were seeded on 60 mm dish and exposed to oxidative stress 
as described above. After 3h of reperfusion (cells in medium with 2% of fetal bovin serum) 
protein were extracted with boiling Laemmli buffer. Primary antibodies used are: anti-Bax 
(w.d. 1:300, sc-23959, Santa Cruz, CA, USA); anti-Bcl-2 (w.d. 1:500, sc-492 , Santa Cruz, CA, 
USA); anti-β actin (w.d. 1:4000, #A5316, Sigma, Germany).  
JC-1 fluorescent probe (Molecular Probes, Eugene, OR, USA) was used to measure loss of 
mitochondrial transmembrane potential after the oxidative stress protocol. In brief, sub-
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group of cells after 1 hour of reperfusion were incubated with medium containing JC-1 (10 
μg/ml) at 37°C for 20 min and then washed twice with PBS. Fluorescent values were acquired 
using a GloMax-Multi Detection System (Promega Corporation, Madison, WI, USA) with 485 
nm and 530 nm as the green excitation and emission wavelengths, respectively, and 535 nm 
and 590 nm as red excitation and emission wavelengths, respectively. The ratio between red 
and green JC-1 florescence was taken as an index of mitochondrial membrane potential [36]. 
 
2.9. Statistical analysis 
Statistical analysis was performed using IBM SPSS program. For real-time PCR data and in 
vitro data Student’s t-Test was used. For protein quantitative analysis One Way Anova plus 
Fisher’s LSD (Least Significant Difference) or plus Bonferroni Post Hoc test was used. Data are 
presented as mean ± SD. A probability value lower than 0.05 was considered as statistically 
significant. 
 
3. Results 
Taking advantage of the ex vivo Langendorff’s heart model, we investigated the changes that 
occur in Nrg1 and ErbB expression in heart tissue following a global ischemia/reperfusion 
challenge (I/R group), or following the postconditioning procedure (PostC group). Infarct 
mass analysis confirmed the effectiveness of PostC procedure in reducing 
ischemia/reperfusion injury (48±16% vs 29±3.5% of risk area, in I/R and PostC respectively; 
p<0.05). LDH analysis corroborated the infarct size data (LDH release was 381±110 in I/R 
group and 188±80 IU in PostC hearts; p<0.05). The molecular analysis was carried out on five 
animals for each condition. 
The expression of Nrg1and ErbB receptors in the left ventricle was analysed using qRT-
PCR; the mRNA level in I/R hearts was compared with the mRNA level observed in PostC 
hearts. Data show that the four ErbB receptor genes are transcripted in adult rat heart (Fig. 
1). After 30 min ischemia and 2 hours reperfusion, the mRNA levels of ErbB1 and ErbB2 did 
not differ significantly from the Sham (Fig. 1a), regardless of PostC procedure. Similar results 
were obtained for the four ErbB4 isoforms (Fig. 1b). Conversely, ErbB3 mRNA (Fig. 1a) 
displayed a 2.8 fold increase after I/R (p<0.05compared to the Sham) and a 2.6 fold increase 
after PostC (P=0.081 with respect to Sham). 
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Nrg1 transcription was also investigated, discriminating between the two isoforms 
alpha and beta. qRT-PCR analysis did not reveal changes in transcription among samples, as 
shown in Fig. 1c.  
The analysis was then shifted from the mRNA level to the protein level, to investigate 
ErbB3 protein expression. The western blot analysis confirmed the expression of ErbB3 
protein in rat adult heart (Fig. 2a). A quantitative analysis revealed an appreciable 
downregulation (p=0.063) of ErbB3 in I/R samples compared to the PostC (Fig. 2a), in partial 
contrast with mRNA analysis. We then analysed a marker of protein translation, namely 
phospho-S6 protein (p-S6), a subunit of ribosome S40 (when S6 subunit is phosphorylated 
the translation is permitted). The analysis revealed that I/R samples have a lower level of p-
S6 when compared to PostC (p=0.012, Fig. 2a). Yet in PostC sample p-S6 was upregulated 
respect to the Sham (p<0.05, Fig. 2a). Furthermore, we checked the expression of Nrdp1, the 
E3 ligase targeting ErbB3, and we found that in I/R group the Nrdp1 mRNA level is 
significantly higher compared to Sham (2.6± 0.9 fold increase, p=<0.05) but not in PostC 
group (Fig. 2b). Nrdp1 protein levels were analyzed in a western blot assay: the protein is 
downregulated in PostC group (p=0.041), but not in I/R group, respect to the Sham group (Fig 
2c). A Student's t-test between PostC and I/R group reveals a statistically relevant difference 
(p< 0.05). These data together could explain the lower amount of ErbB3 protein in I/R 
samples despite the upregulation of ErbB3 mRNA expression. Intriguingly, PostC preserves 
ErbB3 protein.  
Data regarding Nrdp1 suggest that ErbB3 protein absence contributes to the I/R damage 
and that the presence and stability of ErbB3 protein could protect the tissue. So we examined 
in vitro the ability of ErbB3 receptor to defend cells from oxidative damage. H9c2 cells were 
used as a model; because they express ErbB2 and soluble Nrg1, and a barely detectable ErbB3 
and ErbB4 (data not shown), they were transiently transfected for the expression of ErbB3 
receptor, and were subjected to oxidative stress with hydrogen peroxide. In non-transfected 
cells the administration of Nrg1, before or simultaneously to the oxidative stress, had no effect 
on cell survival rate in a MTT test (Fig 3a). The expression of ErbB3 was confirmed with a 
western blot, together with ErbB2 protein constitutively expressed by H9c2 (Fig. 3b). Results 
show that ErbB3-expressing cells tolerate oxidative stress better than control cells (H9c2-
mock) in each treatment evaluated. Nevertheless, the addition of Nrg1 to the medium did not 
increase cell survival rate in H9c2-ErbB3 and H9c2-mock cells (Fig. 3c). We analysed the 
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Bax/Bcl-2 ratio as an indicator of cell apoptosis. We found that in H9c2-ErbB3 cells the ratio, 
after oxidative stress, remains lower respect to H9c2-mock cells (Fig. 3d,e). Moreover, the 
analysis of JC-1 fluorescent probe confirms that ErbB3 expression in H9c2 cells significantly 
limits the reduction of mitochondrial membrane potential with respect to H9c2-mock cells in 
all treatment performed (Fig 3f).   
 
4. Discussion 
To determine whether ErbB receptors and Nrg1 are early affected by the ischemia-
reperfusion injury and PostC treatment, we analyzed mRNA and protein expression levels in 
samples collected from the rat heart injured by global I/R, in a Langendorff’s model which, 
like all experimental paradigms, has advantages and disadvantages [37]. For instance, 
Langendorff’s model allows to perform a global ischemia, subjecting the heart to a 
homogeneous stress insult, and to remove unwanted blood cells, protein and mRNA from the 
myocardium, thus allowing to perform a “clean” molecular analysis. 
The expression analysis of ErbB receptors reveals an upregulation of ErbB3 mRNA after 
ischemic injury, while the expression of the other ErbB receptors is not perturbed. As far as 
we know, this is the first time that ErbB3 mRNA is shown to be regulated in post-ischemic 
heart. Since no statistic differences in ErbB3 expression were detectable between PostC and 
I/R samples, it is likely that this upregulation is mainly a direct early response to the I/R, not 
modifiable with PostC. Yet, PostC can positively affect the translation machinery, thus 
preserving ErbB3 protein synthesis.  
It is known that ErbB2 and ErbB4 mRNA expression is reduced in human and rat heart 
after heart failure [3,38,39]. This was observed also in diabetic animals, showing cardiac 
dysfunctions [40]. It was proposed that the downregulation of ErbB2 and ErbB4 is a late 
characteristic of the chronic heart injury. Here we focused on the early changes occurring in 
gene expression after I/R challenge and PostC, suggesting that in the early-phase ErbB2 and 
ErbB4 are not regulated at transcriptional level.  
ErbB3 mRNA is upregulated after I/R, while for ErbB3 protein only a tendency to 
downregulation in I/R group, but not in PostC samples, can be observed. This tendency is 
considered the effect of a balance between protein synthesis and degradation in the protected 
and non-protected heart. Our data regarding the level of P-S6 provide evidences that after I/R 
injury the cell damage affects also the translation machinery, with a reduction of protein 
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production, and that the PostC procedure can rescue this damage. These data support the idea 
that ribosomal S6 subunit is a convergence point of protective signaling [41]. Moreover, 
Nrdp1 mRNA was upregulated after I/R injury, in line with literature data about Nrdp1 [13]. 
It has been shown that mouse model overexpressing Nrdp1 exhibit a downregulation of 
ErbB3 protein but only after I/R injury [13]. Nrdp1 degrades ErbB3 and our data suggest that 
this mechanism is perturbed after PostC treatment. In fact, we detected lower amount of 
Nrdp1 protein in PostC samples respect to I/R samples. Directly or indirectly mechanical 
PostC can influence ErbB3 protein levels, so we can assume that ErbB3 signalling pathway can 
be part of the protective signalling recruited by PostC treatment. It is well known that PostC 
activates PI3K-Akt pathway [42]. Actually, ErbB3 receptor has six docking sites for the 
binding of PI3K-p85 and this can result in a higher activation of PI3K-Akt pathway respect to 
the other ErbB receptors [43,44]. Zhang et al., observed in mice after coronary artery ligation 
that the phosphorylation of ErbB3 increases respect to the sham, meanwhile ErbB3 protein is 
unchanged [13]. At the time point analyzed we did not observe ErbB3 or AKT 
phosphorylation (data not shown), however we cannot rule out that it occurs in an earlier or 
later time. 
In literature, data about Nrg1 expression in damaged heart are conflicting: in diabetic 
animals Nrg1 protein is reduced [40], while in human failing myocardium Nrg1 expression 
increases [39]. In animal models of heart failure, after an initial upregulation, Nrg1 level 
decreases, coincidently with the development of ventricular hypertrophy and pump failure 
[45].  
In I/R scenario, cardioprotection by Nrg1 induced pharmacological conditioning has 
been described: in vivo Nrg1 pre-conditioning activates the protective PI3K/Akt pathway [46]. 
Similarly, post-conditioning with Nrg1, in both in situ and in isolated murine hearts, exerted a 
cardioprotective effect via PI3K/Akt pathway [47]. The same authors evidenced that Nrg1 
activates this pathway only after I/R injury but not in sham samples. Therefore, we can argue 
that these protective effects involved also ErbB3 post-ischemic upregulation. 
Recently D’Uva et al., demonstrated that transient expression of ErbB2 in adult mice 
heart after I/R injury results in a good functional and anatomical regeneration, and the 
authors postulated that probably treatment with Nrg1 avoids the loss of ErbB2 in 
cardiomyocytes or activates ErbB2 pathway [48]. The pivotal role of ErbB receptors in cell 
survival after hypoxia/reoxygenation has also been observed using zinc pyrithione, which 
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restores the basal zinc levels during I/R and prevents apoptosis by activating PI3K/Akt [49]. 
Since in our data ErbB3 mRNA is upregulated after I/R, we can argue that the cellular 
response to Nrg1 and its beneficial effects are mediated by ErbB2-ErbB3 heterodimer [50]. In 
fact, among ErbB receptors, only ErbB3 and ErbB4 can bind directly Nrg1. Our analysis 
revealed that Nrg1 mRNA does not change significantly after I/R or PostC, at the time point 
investigated. Nevertheless, in PostC ErbB3 protein is upregulated and a protective autocrine 
loop, involving physiological levels of Nrg1 and upregulated ErbB3, can occur. 
To investigate the role of ErbB3 receptor in the context of redox stress, H9c2 cell model 
was used. The in vitro assays demonstrated that the expression of ErbB3 receptor in H9c2 
cells can increase cell survival rate and can ameliorate mitochondrial resistance to oxidative 
stress. Nrg1 should stimulate an increase of cell survival rate in H9c2-ErbB3 cells, however 
H9c2-ErbB3 cells are protected also without exogenous Nrg1 addition, suggesting that ErbB3 
is activated by the overexpression or by the endogenous Nrg1. Similarly to what seen for 
ErbB4 [32], our data suggest that oxidative stress activated ErbB3 signaling and that this 
receptor is involved in the protective adaptation to cardiac oxidative stress.  
It is becoming more and more clear that Nrg1/ErbB system is a potential target for 
therapy in heart failure as highlighted by the promising results obtained in the clinical studies 
with Nrg1 administration [14,15]. However, the intrinsic mechanism of Nrg1 action is not 
completely understood; a better knowledge of Nrg1 and ErbB regulation in 
ischemia/reperfusion injury is now required to ameliorate the cure and increase the heart 
performance after acute myocardial infarction. 
 
5. Conclusions 
This is the first study emphasizing ErbB3 mRNA upregulation in the heart subjected to 
acute I/R challenge. Here, we show that PostC may counterbalance the effects of I/R on ErbB3 
protein downregulation and that ErbB3 receptor transfection in cardiomyocytes inhibits 
death mechanisms activated by redox stress. These novel evidences of a pivotal role for ErbB3 
in the context of I/R and redox biology highlights the importance of studies on these receptors 
not only for the optimization of Nrg1 treatment for heart diseases, but also for the 
development of new cancer therapies with no side effects on heart. 
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Fig. 1 ErbB3 mRNA is upregulated in Langendorff’s model of heart after 
ischemia/reperfusion. The graphs show the results of quantitative real-time PCR analysis on 
heart apexes after ischemia/reperfusion injury performed in Langendorff’s model. (a) ErbB1 
and ErbB2 transcription is not affected by the injury or by the postconditioning treatment at 
the time-point evaluated. ErbB3 transcription is upregulated in I/R. (b) All the ErbB4 
isoforms are not perturbed by the ischemia/reperfusion injury. (c) No changes in 
transcription were detected for Neuregulin1, alpha or beta isoforms. Statistical analysis: One-
way ANOVA was not significant. Student’s t-Test analysis (comparison between Sham and I/R 
or Sham and PostC). *: p<0.05. 
Sham= control group; I/R= ischemia/reperfusion group; PostC= postconditioning group 
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Fig. 2 Analysis of ErbB3, p-S6 protein and Nrdp1 mRNA and protein after 
ischemia/reperfusion injury with or without postconditioning treatment. (a) The graph 
shows the results of the protein quantification (technical triplicate) performed on heart 
apexes after ischemia/reperfusion injury; ErbB3 and p-S6 proteins were normalized to alpha 
sarcomeric actinin protein, using ImageJ program. About ErbB3 a tendency to downregulation 
can be detected for the I/R samples but not for PostC samples. p-S6 protein results 
upregulated in PostC samples compared to Sham (p=0.033) or I/R samples (p=0.012). The 
image shows a representative western blots. (b) The graph shows the results of quantitative 
real-time PCR analysis. Nrdp1 mRNA is upregulated in I/R group (p=0.011) respect to the 
control. (c) The results of a quantitative analysis (technical triplicate) of Nrdp1 protein are 
visible in the graph. Nrdp1 is downregulated in PostC group (p=0.041), but not in I/R group. 
The image shows representative western blot bands of Nrdp1 protein. Three animal's apexes 
were analysed for each group. Statistical analysis: One Way Anova plus Fisher’s LSD test. * 
p<0.05. Sham= control group; I/R= ischemia/reperfusion group; PostC= postconditioning 
group 
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Fig. 3 Oxidative stress in H9c2 cells over-expressing ErbB3. (a) The graph shows the 
results of the thiazolyl blue tetrazolium bromide (MTT) assay in H9c2 cells exposed to 
oxidative stress (100 µM H2O2 for 2 h). The addition of Nrg1 (50 ng/ml) in the medium 
immediately before (for 2 h) or concurrently to the oxidative stress does not affect cell 
survival. The assay was performed as technical seven-fold and biological triplicate. Statistical 
analysis refers to One Way Anova plus Bonferroni Post Hoc test. (b) Representative western 
blot bands, confirming the expression of ErbB3 protein in transfected H9c2 cells. (c) MTT 
analysis was performed to asses cell survival rate of H9c2 expressing ErbB3 exposed to 
oxidative stress. Four conditions were assayed (no stress, H2O2, H2O2 with Nrg1, pre-
treatment with Nrg1). H9c2-ErbB3 tolerate oxidative stress better than control cells (H9c2-
mock). (d) The graph shows the ratio between Bax and Bcl-2 protein in H9c2-ErbB3 and -
mock cells exposed to oxidative stress. (e) Representative western blot of 2 independent 
experiments is shown. (f) The graph illustrates the effects of oxidative stress on 
mitochondrial membrane potential in H9c2-mock and H9c2-ErbB3 cells, analyzed by JC-1 
assay. All treatment values were normalized to mean value of no-stress group either in H9c2-
ErbB3 and H9c2-mock cells. Statistical analysis: Student’s t-Test analysis. *: p<0.05; **: p<0.01 
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